[Effects of rhodiola rosea on oxidative stress and negative emotional states in patients with obstructive sleep apnea]

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Oct;33(10):954-957. doi: 10.13201/j.issn.1001-1781.2019.10.013.
[Article in Chinese]

Abstract

Objective:The aim of this study is to investigate the effects of rhodiola rosea on oxidative stress, anxiety and depression in patients with OSA. Method:Ninety patients with moderate and severe OSA patients with negative emotions diagnosed by PSG, self-rating depression scale (SDS) and self-rating anxiety scale (SAS) were selected from the respiratory department of our hospital from February 2015 to February 2018. According to the random number table method, the patients were randomly divided into non-invasive ventilator group, rhodiola rosea+non-invasive ventilator group and rhodiola rosea group, with 30 cases in each group. Patients in the non-invasive ventilator group were treated with continuous positive airway pressure (CPAP) for 3 months, and those in the rhodiola rosea+non-invasive ventilator group were treated with oral rhodiola capsules for 3 months on the basis of CPAP, and those in the rhodiola rosea treatment group were treated with pure oral rhodiola capsules for 3 months. The changes of SDS and SAS before and after the three groups were compared, and the changes of serum SOD and MDA were detected by immunoenzyme-linked adsorption for comparative analysis. Result:There were no significant differences in SDS and SAS scores between the three groups (P>0.05). SDS and SAS scores of patients in the rhodiola rosea+non-invasive ventilator group decreased after treatment (P<0.05) compared with those in the non-invasive ventilator group. SDS and SAS scores of patients in the rhodiola treatment group increased after treatment (P<0.05). Compared with those in the rhodiola treatment group, SDS and SAS scores of patients in the rhodiola+non-invasive breathing group decreased after treatment (P<0.05). Three group patients were no significant difference in serum SOD and malondialdehyde (MDA) before treatment (P>0.05). Compared with before treatment, serum SOD level were all increased and MDA level were all decreased in the three groups after treatment (P<0.05). Compared with noninvasive breathing unit after treatment, rhodiola+noninvasive breathing unit after treatment in patients with elevated levels of serum SOD, MDA level decreased (P<0.05), and for the treatment group after treatment in patients with serum SOD levels drop, the MDA levels (P<0.05), and the after rhodiola rosea treatment group compared, rhodiola+noninvasive breathing unit after treatment in patients with elevated levels of serum SOD, MDA level decreased (P<0.05). Conclusion:Rhodiola may improve the negative emotions such as anxiety and depression by inhibiting oxygen free radicals and lipid peroxidation in patients with OSA.

目的:探讨红景天对OSA患者氧化应激及焦虑、抑郁负性情绪的影响。 方法:选90例经PSG、自评抑郁量表(SDS)及焦虑自评量表(SAS)评分确诊的中重度OSA合并负性情绪的患者,根据随机数字表法随机分为无创呼吸机组、红景天+无创呼吸机组及红景天组,每组30例,无创呼吸机组患者采取持续气道正压通气(CPAP)治疗3个月,红景天+无创呼吸机组在CPAP基础上给予口服红景天胶囊治疗3个月,红景天治疗组采用单纯口服红景天胶囊治疗3个月。比较3组治疗前后SDS和SAS评分的变化,同时采用免疫酶联吸附法检测SOD和MDA的变化,并进行对比分析。 结果:3组患者治疗前SDS、SAS得分相比,差异无统计学意义(P>0.05);与治疗前比较,3组患者治疗后SDS、SAS评分均下降(P<0.05)。与无创呼吸机组治疗后比较,红景天+无创呼吸机组患者治疗后SDS、SAS评分均下降(P<0.05),红景天组患者治疗后SDS、SAS评分均升高(P<0.05),与红景天治疗组治疗后比较,红景天+无创呼吸机组患者治疗后SDS、SAS评分均下降(P<0.05);3组患者治疗前血清超氧化物歧化酶(SOD)和丙二醛(MDA)相比差异无统计学意义(P>0.05);与治疗前比较,3组患者治疗后血清SOD水平均升高,MDA水平均下降(P<0.05)。与无创呼吸机组治疗后比较,红景天+无创呼吸机组患者治疗后血清SOD水平升高,MDA水平下降(P<0.05),而红景天治疗组患者治疗后血清SOD水平下降,MDA水平升高(P<0.05),与红景天治疗组治疗后比较,红景天+无创呼吸机组患者治疗后血清SOD水平升高,MDA水平下降(P<0.05); 结论:红景天可能通过抑制OSA患者机体氧自由基和脂质过氧化,进而改善患者焦虑、抑郁等负性情绪。.

Keywords: negative emotions; oxidative stress; rhodiola rosea; sleep apnea, obstructive.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Continuous Positive Airway Pressure
  • Humans
  • Malondialdehyde
  • Oxidative Stress / drug effects
  • Plant Extracts / therapeutic use*
  • Rhodiola*
  • Sleep Apnea, Obstructive / drug therapy*
  • Stress, Psychological / drug therapy*

Substances

  • Plant Extracts
  • Malondialdehyde